52.40 +0.16 (0.31%)
After hours: 7:47PM EDT
|Bid||0.00 x 1800|
|Ask||0.00 x 4000|
|Day's Range||51.92 - 52.76|
|52 Week Range||49.96 - 70.05|
|PE Ratio (TTM)||85.64|
|Forward Dividend & Yield||1.60 (3.07%)|
|1y Target Est||N/A|
Exelixis (EXEL) is focused on the label expansion and life cycle management of the cabozantinib franchise in collaboration with Bristol-Myers Squibb (BMY) and Roche Holdings (RHHBY). The above diagram shows the rationale for studying cabozantinib in combination with immunotherapy in multiple cancer indications. Exelixis is currently evaluating the safety and preliminary activity, in terms of objective response rate and progression-free survival, of a combination of cabozantinib with nivolumab and a combination of cabozantinib with nivolumab and ipilimumab in advanced hepatocellular carcinoma (or HCC) indications in an ongoing Phase 2 trial.
In the first quarter, Exelixis’s (EXEL) Cabometyx witnessed more than a 20% sequential rise in prescription volume driven by both new patient starts and a robust rise in the total number of patients on the therapy. According to a report, ~295,000 people across the world are diagnosed with kidney cancer every year, while 134,000 kidney cancer patients die every year. According to the American Cancer Society’s Cancer Facts & Figures 2018, the annual incidence of kidney cancer in the United States is ~65,000, while the annual death toll of the disease is 15,000. Another report estimates that almost 70%–75% of renal cell cancer (or RCC) patients suffer from clear cell RCC.
Today, Immunomedics (IMMU) announced positive results from a Phase 2 trial evaluating its investigational antibody drug conjugate (or ADC) sacituzumab govitecan in patients suffering from estrogen receptor-positive (or ER+)/human epidermal growth factor receptor 2-negative (or HER2-) metastatic breast cancer who have previously received at least two therapies. The investigational ADC therapy demonstrated an overall response rate of 31% in these heavily pretreated patients. Immunomedics plans to file its first biologics license application with the FDA later this month for the approval of sacituzumab govitecan for the treatment of metastatic triple-negative breast cancer (mTNBC).
The company reported net income of close to $115.9 million in the quarter, a YoY rise of ~594% and a sequential rise of 201%. Exelixis reported diluted GAAP (generally accepted accounting principles) EPS (earnings per share) of close to $0.37, a YoY rise of ~585% and a sequential rise of 201%. Analysts expect Exelixis to report revenue of close to $723 million in 2018, a YoY rise of ~59.8%.
On May 11, Exelixis’s (EXEL) closing price was $19.55, almost 12.9% lower than its closing price on May 4. This fall was mainly attributable to unfavorable results released from its Phase 3 IMblaze370 study comparing a combination regimen of Cotellic (cobimetinib) with Roche Holdings’ (RHHBY) Tecentriq (atezolizumab) compared to Bayer’s Stivarga in locally advanced or metastatic colorectal cancer indications. Exelixis and Roche Holdings’ investigational combination regimen failed to demonstrate a statistically significant improvement in the primary end point of overall survival compared to Stivarga in difficult-to-treat patients who had witnessed disease progression or had been unable to tolerate at least two chemotherapy treatments.
Gilead Sciences’ (GILD) Viread sales decreased 63% from $260 million in Q1 2017 to $97 million in Q1 2018. Epclusa sales, which accounted for 12% of Gilead’s total antiviral product sales in the first quarter, decreased from $892 million in Q1 2017 to $536 million in Q1 2018.
On CNBC's "Mad Money Lightning Round" , Jim Cramer said he would not buy Chesapeake Energy Corporation (NYSE: CHK ) because there's too much natural gas. Cramer would take profits in Adaptimmune ...
It's that time again! "Mad Money" host Jim Cramer rang the lightning round bell, which means he gave his take on callers' favorite stocks at rapid speed. Clorox : "Clorox is caught up in this whole vortex of the 10-year Treasury going above 3 percent yield.
After topping the $110 level in March 2018, shares of Nektar Therapeutics (NASDAQ:NKTR) are in a downtrend. It is worth noting that even though Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) and Endo International PLC (NASDAQ:ENDP) are starting to attract investors, NKTR stock is more attractive because of the drug’s inherent properties. Nektar collaborated with Bristol-Myers Squibb Company (NYSE:BMY) to develop NKTR-214 in clinical trials.
Bristol-Myers Squibb (BMY) generated $1.1 billion from operating activities in 1Q18, which compares to $861 million in 1Q17. The increase was primarily attributable to the timing of cash collections and payments in business operations of ~$800 million, partially offset by lower litigation settlement proceeds of ~$500 million related to Merck’s Keytruda in 2017.
Bristol-Myers Squibb’s (BMY) total revenues have increased 5%, from $4.9 billion in 1Q17 to $5.2 billion in 1Q18. For fiscal 2018 and 2019, the company is expected to generate total revenues of $21.7 billion and $22.9 billion, respectively.
Bristol-Myers Squibb’s (BMY) prioritized brands include Opdivo, Eliquis, Orencia, Sprycel, Yervoy, and Empliciti. Total Opdivo sales increased 34%, from $1.1 billion in 1Q17 to $1.5 billion in 1Q18. The drug registered strong growth in the US market as well as non-US markets. Its US sales increased 23%, from $761 million in 1Q17 to $938 million in 1Q18. Opdivo’s non-US sales increased 57%, from $366 million in 1Q17 to $573 million in 1Q18.
Bristol-Myers Squibb’s (BMY) business strategy is to combine the scale and capabilities of a pharmaceutical company with the speed and agility of an innovation-driven biotechnology industry. The company’s strategic priorities include the following: driving business performance continuing to build a strong IO (immuno-oncology) franchise maintaining a diversified product portfolio maintaining a disciplined approach to capital allocation Key developments in 2018
Bristol-Myers Squibb (BMY) is a specialty biopharmaceutical company with operations on a global scale. Of the 22 analysts covering Bristol-Myers Squibb in May, nine of them have given the stock a “buy” or higher rating. Eleven have given it a “hold,” and two have given it a “sell.” The mean rating for the stock is 2.5 with a target price of $59.20, implying an upside potential of 16% over the stock’s closing price of $51.09 on May 9.
On April 15, Merck (MRK) in collaboration with the European Organisation for Research and Treatment of Cancer (or EORTC) announced positive results from the Phase 3 KEYNOTE-054 trial, which highlighted the efficacy of Keytruda as adjuvant therapy for high-risk stage III melanoma patients who have previously undergone surgery.
Merck’s (MRK) Keytruda has managed to secure U.S. Food and Drug Administration (or FDA) approval in ten different indications across seven tumor types: melanoma, urothelial cancer, classical Hodgkin lymphoma, squamous cell carcinoma of head and neck, non-small cell lung cancer (or NSCLC), gastric cancer, and solid tumors that have microsatellite instability (or MSI) or DNA mismatch repair deficiency. The drug has already emerged as the leading immunotherapy in metastatic NSCLC, bladder cancer, and head and neck cancer indications.
In 1Q18, Merck’s (MRK) Keytruda reported global sales close to $1.5 billion, which is a year-over-year (or YoY) rise of around 151%. The rise was attributable to the highest number of new patient starts for Keytruda in the US as compared to other immunotherapy drugs such as Bristol-Myers Squibb’s (BMY) Opdivo and Roche Holdings’ (RHHBY) Tecentriq. The drug has established itself as a leading therapy for metastatic lung cancer in the US.
Legendary venture capital firm Kleiner Perkins Caufield & Byers bought into Redwood City's ARMO BioSciences Inc. in December 2012 when Series A shares sold for $1. It stuck with the company into a January IPO at $17 and now with a $50-per-share buyout by Eli Lilly & Co.
Merck (MRK) expects to report revenues in the range of $41.8 billion and $43 billion in fiscal 2018. At mid-April rates, the company expects a favorable impact of two percentage points attributable to foreign currency fluctuations. Merck has also estimated its non-GAAP earnings per share (or EPS) to fall in the range of $4.16 and $4.28 in fiscal 2018.
In 1Q18, Merck’s revenue grew 6% YoY (year-over-year) to $10.0 billion from $9.4 billion, and its EPS (earning per share) rose to $1.05 from $0.88. In this part, we’ll look at how Merck’s valuation multiples compare.
In 1Q18, Merck’s (MRK) Animal Health segment, which includes drugs and vaccines for animals, saw its revenue grow 13% YoY (year-over-year) to ~$1.1 billion from $939 million, including 7% revenue growth at constant exchange rates and a 6% boost by foreign exchange.
In 1Q18, Eylea generated net global revenue of $1.6 billion compared to $1.3 billion in 1Q17, which reflected a ~20% rise on a YoY (year-over-year) basis.
Yahoo Finance's Jared Blikre joins Seana Smith from the floor of the New York Stock Exchange to discuss the latest market moves.